Stories
Slash Boxes
Comments

SoylentNews is people

posted by Fnord666 on Sunday May 12 2019, @04:02PM   Printer-friendly
from the seems-to-work-in-mice dept.

A research group headed by Professor Pirjo Laakkonen at the University of Helsinki has found a weakness in glioblastoma multiforme (GBM)

Glioblastoma is the most prevalent and also the most lethal type of brain tumour in adults, with no curative treatment currently available. Glioblastomas cannot be surgically completely excised, as the tumour cells are adept at invading tissues and spreading around the brain. In addition, glioblastoma cells are extremely resistant to existing drug therapies.

[...] "Our new research revealed that glioblastoma cells depend on the expression of a gene which produces the MDGI protein. Inhibiting the function of this gene results in the death of the tumour cells," Laakkonen explains.

Using existing drugs with known safety profiles is beneficial in bringing new treatments to market. In this case

What makes this finding particularly interesting is that cell death caused by leakage in the lysosomes of glioblastoma cells can be activated by using drugs that cross the blood-brain barrier. In their studies, Laakkonen's group used an antihistamine known as clemastine.

[...] "Our findings demonstrate that antihistamines and other drugs that increase the permeability of the lysosomal membrane can be considered as an enhancing therapy for patients with glioblastoma alongside established treatments," Laakkonen says.

One can hope that in the not too distant future the phrase 'no curative treatment currently available' will be just a little less common.


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 0) by Anonymous Coward on Sunday May 12 2019, @06:27PM

    by Anonymous Coward on Sunday May 12 2019, @06:27PM (#842727)

    The lysosomal membrane is going to be in all cells, not just tumor cells. And here is what they say about it:

    About 90% cell death was observed with 2 ug/ml clemastine concentration, while 1 ug/ml clemastine concentration killed 50% of BT12 and BT13 cells and 64% of ZH305 cells at day 4 (Fig 6A). No significant cell death was observed when normal human endothelial cells (HuAR2T), normal human astrocytes (NHA), embryonic kidney (HEK293T; Fig 6B) or murine brain endothelial (Fig EV3C) cells were treated at 1–2 ug/ml of clemastine, suggesting a therapeutic window for clemastine treatment in gliomas.

    1) You want to give a dose that kills all the tumor cells or else the tumor will evolve resistance
    2) They say "no significant cell death" at 1-2 ug/ml but their figure 6 shows different. Eg, 50% of the NHA cells were dead by day four. Also, this is only looking out to 4 days, the patient is expected to live much longer than four days and will not want all their brain cells killed.